- Home
- ATPC vs ANL Comparison
ATPC vs ANL Comparison
Compare ATPC & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATPC
- ANL
- Stock Information
- Founded
- ATPC 2016
- ANL 2004
- Country
- ATPC Malaysia
- ANL Cayman Islands
- Employees
- ATPC N/A
- ANL N/A
- Industry
- ATPC Medical/Nursing Services
- ANL
- Sector
- ATPC Health Care
- ANL
- Exchange
- ATPC Nasdaq
- ANL Nasdaq
- Market Cap
- ATPC 58.5M
- ANL 61.8M
- IPO Year
- ATPC N/A
- ANL 2023
- Fundamental
- Price
- ATPC N/A
- ANL $1.73
- Analyst Decision
- ATPC
- ANL Hold
- Analyst Count
- ATPC 0
- ANL 1
- Target Price
- ATPC N/A
- ANL N/A
- AVG Volume (30 Days)
- ATPC 25.1K
- ANL 10.9K
- Earning Date
- ATPC 11-13-2025
- ANL 10-21-2025
- Dividend Yield
- ATPC N/A
- ANL N/A
- EPS Growth
- ATPC N/A
- ANL N/A
- EPS
- ATPC N/A
- ANL N/A
- Revenue
- ATPC $1,445,601.00
- ANL N/A
- Revenue This Year
- ATPC N/A
- ANL N/A
- Revenue Next Year
- ATPC N/A
- ANL N/A
- P/E Ratio
- ATPC N/A
- ANL N/A
- Revenue Growth
- ATPC 4.90
- ANL N/A
- 52 Week Low
- ATPC $0.90
- ANL $1.10
- 52 Week High
- ATPC $2.93
- ANL $3.89
- Technical
- Relative Strength Index (RSI)
- ATPC N/A
- ANL N/A
- Support Level
- ATPC N/A
- ANL N/A
- Resistance Level
- ATPC N/A
- ANL N/A
- Average True Range (ATR)
- ATPC 0.00
- ANL 0.00
- MACD
- ATPC 0.00
- ANL 0.00
- Stochastic Oscillator
- ATPC 0.00
- ANL 0.00
About ATPC Agape ATP Corporation
Agape ATP Corp through its subsidiaries is engaged in providing health and wellness products and health solution advisory services. The principal activities of the company is to supply high-quality health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation, anti-aging and products designed to improve the overall health system of the human body and various wellness programs. Its segments include: Skin care, health and wellness segment includes the provision of health and wellness products and health solution advisory services; and Green energy segment includes providing renewable energy products, technical solutions, installations and maintenance services. It derives maximum revenue from Skin care, health and wellness segment.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.